Spirit Scientific (7790) showcased its patented Platelet Lyophilized Treatment (PLT) technology at the 2025 Regenerative Medicine Expo TOKYO from July 9–11. This technology distinguishes itself from traditional PRP therapy by offering fixed dosage and concentration, safety, and long-term storage at room temperature, enabling more precise regenerative medical applications.
The company is strategically expanding into the Japanese market via its subsidiary, Spirit Scientific Japan Co., Ltd., with a new laboratory in Tokyo already entering trial operations. Spirit Scientific has a proven track record in Taiwan, having completed over 36,000 PLT preparations and partnering with more than 1,300 medical institutions across fields such as orthopedics, medical aesthetics, and dermatology.
Chairman Lin Dao-long highlighted the company’s “Biofoundry™” model, which merges clinical application with standardized manufacturing processes. Following the Tokyo event, Spirit Scientific will participate in the Bio Asia-Taiwan Expo (July 24–27) to feature its BMLT® and premium lyophilization services.
新聞來源: https://news.gbimonthly.com/tw/article/show.php?num=78517
